Dongin (Donoven) Kim, Ph.D.
Assistant Professor
Pharmaceutical Sciences
Phone (405) 271-6593 x 47473
Alt Phone (801) 574-6823 (cell)
Office College of Pharmacy, CPB 317
Email dongin-kim@ouhsc.edu
Publications & Presentations
- 11. Kim Y, Youn Y S, Oh K T, Kim D, Lee E S. Tumor-Targeting Liposomes with Transient Holes Allowing Intact Rituximab Internally. Biomacromolecules. 2020
12. Kang C, Han P, Lee J S, Lee D, Kim D. Anchor, Spacer, and Ligand-Modified Engineered Exosomes for Trackable Targeted Therapy. Bioconjugate chemistry. 2020; 31 : 2541-2552
13. Yoon S, Kim Y, Youn Y S, Oh K T, Kim D, Lee E S. Transferrin-Conjugated pH-Responsive γ-Cyclodextrin Nanoparticles for Antitumoral Topotecan Delivery. Pharmaceutics. 2020; 12
14. Lee E, Park J, Youn Y S, Oh K T, Kim D, Lee E S. Alendronate/cRGD-Decorated Ultrafine Hyaluronate Dot Targeting Bone Metastasis. Biomedicines. 2020; 8
15. Kang M, Tang B, Li J, Zhou Z, Liu K, Wang R, Jiang Z, Bi F, Patrick D, Kim D, Mitra A K, Yang-Hartwich Y. Identification of miPEP133 as a novel tumor-suppressor microprotein encoded by miR-34a pri-miRNA. Molecular cancer. 2020; 19 : 143
Grants
- 6. Role of Renal Lymphatics in Blood Pressure Regulation. NIH. Start Date: 2018. End Date: 2023.
7. Cancer exosome mediated antibody production for active tumor targeting treatment. Non-federal. Start Date: 2022. End Date: 2023.
8. Engineering Exosome for Ovarian Cancer Targeting Therapy. NIH. Start Date: 2021. End Date: 2023.
9. Exosome based intraocular therapy combined with active targeting of ocular neovascularization. NIH. Start Date: 2022. End Date: 2022.
10. Translational Studies on Extracellular Vesicles in Ovarian Cancer. Non-federal. Start Date: 2022. End Date: 2022.
Awards and Honors
no results
Education
- 1. Degree: Ph D. University of Utah. Date: 2009.
2. Degree: MS. University of Florida. Date: 2002.
3. Degree: BS. Ajou University. Date: 1999.
Administrative Assignments
no results